tbuckley/cabot-search huggingface dataset:
MA18.05 Diagnostic Difference Between Neuroendocrine Markers in Pulmonary Cancers: A Comprehensive Study and Review of the Literature
Authors: H. Brunnström, J. Staaf, L. Tran, L. Söderlund, B. Nodin, K. Jirström, H. Vidarsdottir, M. Planck, J. Mattsson, J. Botling, P. Micke
Journal: Journal of Thoracic Oncology (2019)
EP1.04-20 Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC
Authors: A. Lisberg, B. Liu, R. Salehi-Rad, J.M. Lee, L. Tran, K. Krysan, R. Li, Y. Lin, A. Tseng, F. Abtin, R. Suh, S. Oh, D. Aberle, L. Winter, W.D. Wallace, D. Elashoff, E. Garon, S. Sharma, S. Dubinett
Journal: Journal of Thoracic Oncology (2019)
P2.22 Immunotherapy-related Thrombosis: Considerations and Associated Factors in Non-small Cell Lung Cancer (NSCLC) Patients
Authors: A.F. Cardona, O. Arrieta, A. Ruiz-Patiño, L. Zatarain Barron, L. Corrales-Rodriguez, C. Martín, F. Barrón, C. Sotelo, J. Rodríguez, L. Ricaurte, J. Ávila, D. Mayorga, P. Archila, H. Freitas, V.C. Cordeiro De Lima, L. Mas, J. Otero, H. Carranza, C. Vargas, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection
Authors: Man‐Fung Yuen, Ingolf Schiefke, Jung‐Hwan Yoon, Sang Hoon Ahn, Jeong Heo, Ju Hyun Kim, Henry Lik Yuen Chan, Ki Tae Yoon, Hartwig Klinker, Michael Manns, Joerg Petersen, Thomas Schluep, James Hamilton, Bruce D. Given, Carlo Ferrari, Ching‐Lung Lai, Stephen A. Locarnini, Robert G. Gish
Journal: Hepatology (2019)

ARC-520, the first an RNA interference (RNAi) therapeutic, was designed to reduce all RNA transcripts derived from covalently closed circular DNA, leading to a reduction in viral antigens and hepatitis B virus (HBV) DNA.We aimed to evaluate the depth of hepatitis B surface antigen (HBsAg) decline in response to multiple doses of ARC-520 compared to placebo (PBO) in two randomized, multicenter studies in nucleoside/nucleotide analogue reverse-transcriptase inhibitor (NUC)-experienced patients with hepatitis B early antigen (HBeAg)-negative (E-neg) or HBeAg-positive (E-pos) disease. A total of 58 E-neg and 32 E-pos patients were enrolled and received four monthly doses of PBO (n = 20 E-neg, 11 E-pos), 1 mg/kg ARC-520 (n = 17 E-neg, 10 E-pos), or 2 mg/kg ARC-520 (n = 21 E-neg, 11 E-pos) concomitantly with NUC. HBsAg change from baseline to 30 days after the last ARC-520 dose were compared to PBO. Both E-neg and E-pos high-dose groups significantly reduced HBsAg compared to PBO, with mean reductions of 0.38 and 0.54 log IU/mL, respectively. HBsAg reductions persisted for approximately 85 days and >85 days after the last dose in E-neg and E-pos patients, respectively. The low-dose groups did not reach statistical significance in either study. E-pos patients showed a dose-dependent reduction in HBeAg from baseline. Mean maximum reduction was 0.23 and 0.69 log Paul Ehrlich IUs/mL in the low-dose and high dose ARC-520 groups respectively. ARC-520 was well tolerated, with only two serious adverse events of pyrexia possibly related to study drug observed.ARC-520 was active in both E-neg and E-pos, NUC-experienced HBV patients; but absolute HBsAg reductions were moderate, possibly due to expression of HBsAg from integrated HBV DNA, indicating the need for RNAi therapeutics that can target viral transcripts regardless of origin.
Consultant suspended for vulgar comments is struck off for lack of remediation
Authors: Clare Dyer
Journal: BMJ (2019)

A hospital consultant who was suspended from the UK medical register over sexual and profane comments to colleagues and patients has been struck off after he failed to provide a review hearing with any evidence of remediation, remorse, or insight.

Serban Gheorghiu seemed unaware of professional boundaries, said five nurses from York Teaching Hospital NHS Foundation Trust and other witnesses who testified at the medical practitioners tribunal that suspended him for nine months in January.1

That tribunal found that he routinely asked nurses about their …
P2.10-16 Lung Cancer Occurrence Attributable to Passive Smoking Among Never Smokers in China: A Systematic Review and Meta-Analysis
Authors: Y. Du, X. Cui, G. Sidorenkov, H. Groen, R. Vliegenthart, M. Heuvelmans, S. Liu, M. Oudkerk, G. De Bock
Journal: Journal of Thoracic Oncology (2019)
A green tea–triggered genetic control system for treating diabetes in mice and monkeys
Authors: Jianli Yin, Linfeng Yang, Lisha Mou, Kaili Dong, Jian Jiang, Shuai Xue, Ying Xu, Xinyi Wang, Ying Lu, Haifeng Ye
Journal: Science Translational Medicine (2019)

A green tea–triggered genetic control system was developed for genome/epigenome editing, digital computations, and diabetes therapy in mice and monkeys.
Purifying Selection in Corvids Is Less Efficient on Islands
Authors: Verena E Kutschera, Jelmer W Poelstra, Fidel Botero-Castro, Nicolas Dussex, Neil J Gemmell, Gavin R Hunt, Michael G Ritchie, Christian Rutz, R Axel W Wiberg, Jochen B W Wolf
Journal: Molecular Biology and Evolution (2019)

Abstract Theory predicts that deleterious mutations accumulate more readily in small populations. As a consequence, mutation load is expected to be elevated in species where life-history strategies and geographic or historical contingencies reduce the number of reproducing individuals. Yet, few studies have empirically tested this prediction using genome-wide data in a comparative framework. We collected whole-genome sequencing data for 147 individuals across seven crow species (Corvus spp.). For each species, we estimated the distribution of fitness effects of deleterious mutations and compared it with proxies of the effective population size Ne. Island species with comparatively smaller geographic range sizes had a significantly increased mutation load. These results support the view that small populations have an elevated risk of mutational meltdown, which may contribute to the higher extinction rates observed in island species.
MA20.03 DNA Methylation of MT1A and NPTX2 Genes Predict Malignant Behavior of Thymic Epithelial Tumors
Authors: K. Muguruma, K. Kondo, R. Kishibuchi, M. Tsuboi, S. Soejima, B. Tegshee, K. Kajiura, Y. Kawakami, N. Kawakita, M. Yoshida, H. Takizawa, A. Tangoku
Journal: Journal of Thoracic Oncology (2019)
Dendritic Cell Vaccination Combined with Pomalidomide and Dexamethasone Ameliorated Antitumor Immunity By Skewing Immuno-Suppressive Status Toward Immuno-Supportive Status in a Murine Myeloma Model
Authors: Sung-Hoon Jung, Seoyun Yang, Hyun-Ju Lee, Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2017)
US hospital algorithm discriminates against black patients, study finds
Authors: Owen Dyer
Journal: BMJ (2019)

A computer algorithm used by many US hospitals to predict risk and allocate follow-up resources directs significantly more extra care to white than to black patients with the same disease burden, shows an analysis published in Science .1

The researchers did not name the particular algorithm but called it “one of the largest and most typical examples of a class of commercial risk-prediction tools that, by industry estimates, are applied to roughly 200 million people in the United States each year.”

The algorithm is undermined by its use of previous health expenditure as the metric by which to judge patients’ health needs, the study found. It has long been known that black patients’ health expenditure …
P2.12-11 Quality of Life in ALTER1202 Trial of Anlotinib as Third-or Further Line Therapy for Advanced Small Cell Lung Cancer (SCLC): A Post-Hoc Analysis
Authors: K. Li, Y. Cheng, Q. Wang, J. Shi, B. Han, L. Wu, G. Chen, J. He, J. Wang, H. Qin, X. Li
Journal: Journal of Thoracic Oncology (2019)
P2.11-39 Multimodal Monitoring of Patient-Derived Early-Stage Lung Adenocarcinoma with the Chicken Chorioallantoic Membrane System
Authors: E. Koziolek, B. Villegas, G. Abdelhady, J. Liu, J. Barrio, W. Wallace, J. Yanagawa, D. Shackelford, S. Dubinett, C. Scafoglio
Journal: Journal of Thoracic Oncology (2019)
Randomized prospective phase 3 trial of <sup>68</sup>Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].
Authors: Jeremie Calais, Johannes Czernin, Wolfgang P Fendler, David Elashoff, Nicholas George Nickols
Journal: Journal of Clinical Oncology (2019)

TPS5101 Background: Salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence after prostatectomy offers long-term biochemical control in about 50–60% of patients. SRT is commonly initiated in patients with serum PSA levels &lt; 1 ng/mL, a threshold at which standard-of-care imaging is insensitive for detecting recurrence. As such, SRT target volumes are usually drawn in the absence of radiographically visible disease. 68Ga-PSMA-11 (PSMA) PET/CT molecular imaging is highly sensitive and may offer anatomic localization of PCa biochemical recurrence. However, it is unclear if incorporation of PSMA PET/CT imaging into the planning of SRT could improve its likelihood of success. The purpose of this trial is to evaluate the success rate of SRT for recurrence of PCa after prostatectomy with and without planning based on PSMA PET/CT. Methods: We will randomize 193 patients to proceed with standard SRT (control arm 1, n = 90) or undergo a PSMA PET/CT scan (free of charge for patients) prior to SRT planning (investigational arm 2, n = 103). The primary endpoint is the success rate of SRT measured as biochemical progression-free survival (BPFS) after initiation of SRT. Biochemical progression is defined by PSA ≥ 0.2 ng/mL and rising. The randomization ratio of 1:1.13 is based on the assumption that approximately 13% of subjects randomized to Arm 2 will not be treated with SRT because of PSMA-positive extra-pelvic metastases. These patients will not be included in the primary endpoint analysis but will still be followed. The choice of treating the prostate bed alone vs prostate bed and pelvic lymph nodes, with or without androgen deprivation therapy (ADT), is selected by the treating radiation oncologist. The radiation oncologist may change the radiation plan depending on the findings of the PSMA PET/CT scan. Any other imaging is allowed for SRT planning in both arms if done per routine care. Patients will be followed until either one of the following conditions occur: 5 years after the date of initiation of randomization, biochemical progression, diagnosis of metastatic disease, initiation of any additional salvage therapy, death. Discussion: This is the first randomized phase 3 prospective trial designed to determine whether PSMA PET/CT molecular imaging can improve outcomes in patients with PCa early BCR following radical prostatectomy. Clinical trial information: NCT03582774.
P2.03-22 Chromate Exposure Induces DNA Hypermethylation of the Mismatch Repair Gene MLH1 in Lung Cancer
Authors: K. Kondo, M. Tsuboi, S. Soejima, N. Kawakita, H. Toba, Y. Kawakami, M. Yoshida, H. Takizawa, A. Tangoku
Journal: Journal of Thoracic Oncology (2019)
EP1.16-34 Survival Analysis of Icotinib for Brain Metastases in EGFR Mutated Non-Small Cell Lung Cancer
Authors: Y. Zhu, C. Xu, W. Wang, L. Wu, H. Chen, X. Li, C. Xu, W. Zhuang, K. Du, M. Fang
Journal: Journal of Thoracic Oncology (2019)
EP1.04-45 Relevance of Antibiotic Use on Clinical Activity of Immune Checkpoint Inhibitors in Hispanic Patients with Advanced NSCLC (CLICAP-ABs)
Authors: F. Barrón, O.G. Arrieta, A.F. Cardona, A. Ruiz-Patiño, Z.L. Zatarain Barrón, L.L. Rojas, L. Corrales, C. Martin, C. Sotelo, J. Rodriguez, J. Ávila, M. Bravo, D. Mayorga, P. Archila, L. Mas, H. Freitas, V. Cordeiro De Lima, J. Otero, H. Carranza, C. Vargas, R. Rosell
Journal: Journal of Thoracic Oncology (2019)
The Realities of External Validity in Global Surgery Research—Reply
Authors: Sherry M. Wren, Adam L. Kushner
Journal: JAMA Surgery (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
P2.18-03 Salvage Surgery After Curative-Intent Chemo and/or Radiation for Locally Advanced Lung Cancer
Authors: M. Yamashita, Y. Maki, T. Ueno, H. Suehisa, D. Harada, T. Kozuki, N. Nogami, M. Kataoka
Journal: Journal of Thoracic Oncology (2019)
P2.14-29 Clinical Impact of Next-Generation Sequencing (NGS) in Blood Liquid Biopsies for Treatment Decisions in Advanced NSCLC
Authors: M. Garcia Pardo, I. Martinez Delfrade, I. Aparicio Salcedo, M. Arregui Valles, M. Alva Bianchi, V. Tirado Anula, R. Alvarez, A. Calles Blanco
Journal: Journal of Thoracic Oncology (2019)
MA18.10 Multicenter Study of Intraoperative Rapid IHC for Undiagnosed Pulmonary Tumor Using Non-Contact Alternating-Current Electric-Field Mixing
Authors: K. Imai, S. Takashima, N. Kurihara, M. Atari, T. Matsuo, S. Watanabe, H. Iwai, H. Suzuki, Y. Minamiya, Y. Tanaka, Y. Maniwa
Journal: Journal of Thoracic Oncology (2019)
PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study
Authors: L. Paz-Ares, Y. Chen, N. Reinmuth, K. Hotta, D. Trukhin, G. Statsenko, M.J. Hochmair, M. Özgüroğlu, J.H. Ji, O. Voitko, A. Poltoratskiy, S. Ponce, F. Verderame, L. Havel, I. Bondarenko, A. Kazarnowicz, G. Losonczy, N.V. Conev, J. Armstrong, N. Byrne, N. Shire, H. Jiang, J. Goldman
Journal: Journal of Thoracic Oncology (2019)
Which emollients are effective and acceptable for eczema in children?
Authors: Matthew J Ridd, Amanda Roberts, Douglas Grindlay, Hywel C Williams
Journal: BMJ (2019)

What you need to know• Although emollients alone can help reduce the symptoms of eczema and prevent flares, most people will need to use anti-inflammatory treatments such as topical corticosteroids of an appropriate strength and duration as well• Effectiveness and acceptability of emollients varies according to disease severity, body site, climate, container, and patient or carer preferences and beliefs• Based on current evidence, the "best" emollient is the one that the individual prefers after a period of testing
Challenges of developing sports medicine in the Netherlands … work in progress!
Authors: Fred Hartgens, Frank J G Backx
Journal: British Journal of Sports Medicine (2019)

Sports medicine was finally recognised as a full medical specialty in the Netherlands, comparable with the position of orthopaedic surgeons and cardiologists, on 1 July 2014; nearly 50 years after the Dutch Association of Sports Medicine (VSG) was founded by a handful of enthusiastic pioneers on 8 May 1965. From these humble beginnings, sports medicine gradually gathered momentum and a 4-year full-time training, similar to that seen in other medical disciplines, was introduced in 1991. These pioneers were regarded as ‘upstarts’ in the Dutch healthcare system, but by combining their efforts from the start, and by focusing on the single goal to make sports medicine a new medical specialty, they were able to create new opportunities (and challenges) for young doctors with an interest in sport.

Sports medicine includes prevention, diagnostics, treatment and rehabilitation, with a view to maintain or improve performance at every level. As with every medical specialty, there is a constant need to extend our knowledge, and expertise, and to make the latest advances more accessible to athletes, players, parents and coaches. To achieve this the VSG, in close collaboration with the majority of the 150 sports medicine specialists, developed a science agenda to address the challenges that were anticipated in the upcoming years. Among the main topics identified were overuse …
P2.04-11 Overcoming Resistance to Immunotherapy Using CVA21: Initial Results from a Phase II Study
Authors: C. Senko, M. Klevansky, G. Peters, P. Mitchell, S. White, S. Arulananda, A. Zimet, K. Asadi, J. Smith, N. Micaleff, J. Palmer, T. Morgan, O. Klein, J. Cebon, T. John
Journal: Journal of Thoracic Oncology (2019)
OA12.03 Initial Reporting of NRG-LU001, Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
Authors: H. Skinner, C. Hu, T. Tsakiridis, R. Santana-Davila, B. Lu, J. Erasmus, A. Doemer, G. Videtic, J. Coster, A. Yang, R. Lee, M. Werner Wasik, P. Schaner, S. Mccormack, B. Esparaz, R. Mcgarry, J. Bazan, T. Stuve, J. Bradley
Journal: Journal of Thoracic Oncology (2019)
OA14.06 Hyperprogressive Disease in Advanced Non–Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors
Authors: G. Lo Russo, D. Signorelli, C. Proto, G. Galli, A. Prelaj, R. Ferrara, M. Sommariva, M. Moro, V. Cancila, M. Ganzinelli, S. Brich, S. Sangaletti, G. Pruneri, C. Tripodo, M.P. Colombo, L. Rivoltini, A. Balsari, G. Sozzi, M. Boeri, M. Garassino
Journal: Journal of Thoracic Oncology (2019)
P1.01-57 Association of Initial PD-L1 Expression with T790M-Acquired Resistance in Advanced EGFR-Mutant Lung Adenocarcinoma Patients
Authors: K. Nishino, A. Kubota, K. Kunimasa, M. Kimura, T. Inoue, M. Tamiya, H. Kuhara, T. Kumagai
Journal: Journal of Thoracic Oncology (2019)
P2.09-34 Next-Generation Sequencing Implementation in Non-Small Cell Lung Cancer Molecular Diagnosis
Authors: S. Clavé, B. Bellosillo, M. Salido, G. Tagmouti, Á. Taus, P. Rocha, M. Hardy-Werbin, L. Moliner, X. Riera, C. Fernández-Rodríguez, E. Arriola, L. Pijuan
Journal: Journal of Thoracic Oncology (2019)
P2.14-09 Concurrent TP53 Mutation Adversely Impact the Efficacy of Crizotinib in ROS1-Rearranged Lung Cancer Patients
Authors: G. Lin, H. Xu, J. Zhao, J. Kong, X. Ai, F. Yu, K. Du, L. Zhu, L. Li, H. Ma, Q. Wang, H. Xiong, R. Chen, X. Xia
Journal: Journal of Thoracic Oncology (2019)
OA03.05 Characterization of Genomic Alterations in Chinese LCNEC and SCLC via Comprehensive Genomic Profiling
Authors: L. Wu, L. Cao, L. Chen, B. Zhu, X. Hu, G. Lin, Y. Lin, S. Zhang, W. Peng, M. Jiang, X. Mao, T. Zhang, J. Ye, L. Zhang
Journal: Journal of Thoracic Oncology (2019)
P2.11-11 Exosomal miRNAs as Diagnosis Biomarkers for Distinguishing Benign and Malignant Nodules in Non-Small Cell Lung Cancer
Authors: D. Zheng, Y. Yang, C. Wu, H. Wang, S. Liu, X. Xu, D. Zhang, F. Li, J. Ni, J. Xu, G. Jiang
Journal: Journal of Thoracic Oncology (2019)
P2.13-05 Endobronchial Ultrasound for Mediastinal Restaging in Non-Small Cell Lung Cancer
Authors: S. Baeza Mena, C. Centeno Clemente, P. Serra Mitja, C. Martinez-Barenys, E. Carcereny, T. Moran, E. Castella Fernandez, J. Jove Teixido, A. Rosell, F. Andreo García
Journal: Journal of Thoracic Oncology (2019)
Boron neutron capture therapy: moving towards targeted therapy for locally recurrent head and neck squamous cell carcinoma
Authors: Ying Sun
Journal: Military Medical Research (2019)

Locally recurrent head and neck squamous cell carcinoma (HNSCC) is often unresectable, and a repeat course of radiotherapy is associated with incremental toxicities. Boron neutron capture therapy (BNCT) is a novel targeted radiotherapy modality that can achieve a high dose gradient between cancerous and adjacent normal tissues. However, the relationships among the dose resulting from BNCT, tumor response to BNCT, and survival are not completely understood. Recently, a study published in Radiotherapy and Oncology investigated the efficacy of BNCT in the treatment of patients with locally recurrent HNSCC and the factors associated with favorable treatment response and survival. In this article, the findings, strengths and limitations of this study are discussed in depth, and the significance of the study and motivations for future research are highlighted.
P2.04-73 Maintenance Treatment Using CimaVax EGF Vaccine. Experience of Single Institution
Authors: Y. Flores, D. Páramo, S. Alsina, L. Alsina, I. Inguanzo, J. Rodríguez, A. Elejalde, E. Flores, J. Lamadrid, D. Corrales, R. Ropero, E. Gracia, G. Gondori
Journal: Journal of Thoracic Oncology (2019)
Treatment of Myeloproliferative Neoplasms in Blastic Phase with Azacytidine. Clinical Results and Identification of Prognostic Factors
Authors: Alessandro Andriani, Marco Montanaro, Massimo Breccia, Pasquale Niscola, Marianna Criscuolo, Nicoletta Villivà, Giulio Trapè, Antonia Centra, Ambra Di Veroli, Maria Teresa Voso, Robin Foà, Roberto Latagliata
Journal: Blood (2017)
P2.14-23 Initial Analysis in NSCLC Part of Randomized Trial Evaluating Topical Corticosteroid for the Facial Acneiform Rash by EGFR Inhibitors
Authors: Y. Fujiwara, K. Nishino, M. Tamiya, K. Kikuchi, R. Saito, T. Kobayashi, T. Hamaguchi, K. Nozawa, H. Fukuda, Y. Kiyohara, N. Yamazaki
Journal: Journal of Thoracic Oncology (2019)
Abstract 17130: Variables Associated With Uncontrolled Blood Pressure Early After Stroke
Authors: Saviour Achilike, Austin Wang, Gabretta Cooksey, Evelyn Hinojosa, Munachi Okpala, M C Denny, Sean I Savitz, Anjail Sharrief
Journal: Circulation (2018)

Introduction: Uncontrolled blood pressure (BP) is a major risk factor for recurrent stroke; however, up to 50% of stroke survivors have uncontrolled BP 6 months after stroke. Characterization of factors associated with uncontrolled BP early after stroke discharge (DC) may help to identify patients for BP interventions. Hypothesis: We sought to identify factors associated with uncontrolled BP in the first month after stroke discharge. We hypothesized that African American (AA) race, insurance status, medication complexity, and hospital BP prior to discharge would be associated with uncontrolled BP. Methods: We identified hypertensive patients with ischemic or hemorrhagic stroke or transient ischemic attack scheduled to follow-up in the stroke clinic 2 to 4 weeks after hospital DC. Office BP was obtained using BpTRU, an automated machine that averages five unattended BP measures. Uncontrolled BP was defined using 2017 American College of Cardiology Guidelines as BP ≥ 130/80 mmHg. We used univariate logistic regression to assess relationships between uncontrolled BP and selected variables. Variables with statistically significant associations in the univariate models and variables associated with uncontrolled BP in the literature were included in the multiple logistic regression model. Results: Of the 230 patients identified, 55.7% had uncontrolled BP at clinic follow-up. In univariate and multivariable analyses, AA race, young stroke (age &lt; 50), and systolic BP (SBP) 24-hours prior to DC were significantly associated with uncontrolled BP early after stroke DC. BP medication complexity was not associated with uncontrolled BP in this study. Conclusions: AA race, young age, and elevate SBP in the 24 hours prior to of stroke DC were associated with uncontrolled BP early after stroke. These variables can be used to identify patients who may benefit from early interventions aimed at reducing the risk of uncontrolled BP after stroke and stroke recurrence.
Influenza restriction factor MxA functions as inflammasome sensor in the respiratory epithelium
Authors: SangJoon Lee, Akari Ishitsuka, Masayuki Noguchi, Mikako Hirohama, Yuji Fujiyasu, Philipp P. Petric, Martin Schwemmle, Peter Staeheli, Kyosuke Nagata, Atsushi Kawaguchi
Journal: Science Immunology (2019)

MxA inflammasome restricts influenza A virus infection in respiratory epithelium.